3,970 reports of this reaction
3.7% of all APIXABAN reports
#1 most reported adverse reaction
ATRIAL FIBRILLATION is the #1 most commonly reported adverse reaction for APIXABAN, manufactured by Amneal Pharmaceuticals of New York LLC. There are 3,970 FDA adverse event reports linking APIXABAN to ATRIAL FIBRILLATION. This represents approximately 3.7% of all 106,298 adverse event reports for this drug.
Patients taking APIXABAN who experience atrial fibrillation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ATRIAL FIBRILLATION is moderately reported among APIXABAN users, representing a notable but not dominant share of adverse events.
In addition to atrial fibrillation, the following adverse reactions have been reported for APIXABAN:
The following drugs have also been linked to atrial fibrillation in FDA adverse event reports:
ATRIAL FIBRILLATION has been reported as an adverse event in 3,970 FDA reports for APIXABAN. This does not prove causation, but indicates an association observed in post-market surveillance data.
ATRIAL FIBRILLATION accounts for approximately 3.7% of all adverse event reports for APIXABAN, making it one of the most commonly reported side effect.
If you experience atrial fibrillation while taking APIXABAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.